Oral SERDs alone or in combination with CDK 4/6 inhibitors in breast cancer: Current perspectives and clinical trials

Over the past few decades, first-line therapy for treating advanced and metastatic HR+/HER2-breast cancer has transformed due to the introduction of adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitors (CDK 4/6i). However, there is an unmet need for novel classes of endocrine thera...

Full description

Bibliographic Details

Published in:	Breast
Main Authors:	Kleoniki Apostolidou, Eleni Zografos, Maria Alkistis Papatheodoridi, Oraianthi Fiste, Meletios Athanasios Dimopoulos, Flora Zagouri
Format:	Article
Language:	English
Published:	Elsevier 2024-06-01
Subjects:	Hormone receptor positive Advanced breast cancer Oral SERDs CDK 4/6 inhibitors Clinical trials
Online Access:	http://www.sciencedirect.com/science/article/pii/S0960977624000602